Enhertu
Safety Classified by Officially
Enhertu Active substance Trastuzumab deruxtecan Holder Daiichi Sankyo Belgium N.V.-S.A Status Running Indication treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and who have no satisfactory treatment options Public documents Approbation Information for the patient Informed consent …
This is an extract. The publication continues at the source.
Read the original at the source: https://www.famhp.be/nl/menselijk_gebruik/geneesmiddelen/geneesmiddelen/onderzoek_ontwikkeling/gebruik_in_schrijnende_279
Officially imported this from Federal Agency for Medicines and Health Products (FAMHP)’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Federal Agency for Medicines and Health Products (FAMHP) — imported from official source
- Official source
- https://www.famhp.be/en/rss.xml RSS
- Imported
- November 09, 2026 08:32
- Versions
- 1 recorded
- Identity
-
110438 at https://www.famhp.be